par Body, Jean-Jacques 
;Greipp, Philip;Coleman, Robert;Facon, Thierry;Geurs, Filip;Fermand, Jean-Paul;Harousseau, Jean-Luc;Lipton, Allan;Mariette, Xavier;Williams, Catherine;Nakanishi, Arline;Holloway, Donna;Martin, Steven;Dunstan, Colin;Bekker, Pirow
Référence Cancer, 97, 3 Suppl, page (887-892)
Publication Publié, 2003-02
;Greipp, Philip;Coleman, Robert;Facon, Thierry;Geurs, Filip;Fermand, Jean-Paul;Harousseau, Jean-Luc;Lipton, Allan;Mariette, Xavier;Williams, Catherine;Nakanishi, Arline;Holloway, Donna;Martin, Steven;Dunstan, Colin;Bekker, PirowRéférence Cancer, 97, 3 Suppl, page (887-892)
Publication Publié, 2003-02
Article révisé par les pairs
| Résumé : | Osteoprotegerin (OPG) is a decoy receptor for OPG ligand (OPGL), or receptor activator of NF-kappaB ligand (RANKL). RANKL/RANK interaction is important in terminal differentiation and activation of osteoclasts. In binding to RANKL, OPG blocks differentiation and activation of osteoclasts. AMGN-0007 is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease. |
